Progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of the American Society of Clinical Oncology / 中华肿瘤杂志

Soft tissue sarcoma (STS) is a group of rare malignant tumors originating from mesenchymal tissue, with a high degree of malignancy and a wide range of pathological subtypes. The prognosis varies among different subtypes, and treatment increasingly relies on selecting appropriate treatment methods for different subtypes. Surgical treatment is still the main treatment method at present, and the development of immune and targeted therapy also brings new hope for the treatment of soft tissue sarcoma. Immune checkpoint inhibitors, oncolytic viruses and T cell therapy have shown well safety and efficacy in clinical trials. Targeted drugs such as trabectedin and lenvatinib have changed the treatment pattern of soft tissue sarcoma. Currently, chemotherapy based on doxorubicin and ifosfamide is still the first line treatment for patients with advanced soft tissue sarcoma who have distant metastasis. However, the adverse reactions of doxorubicin limit its application in elderly patients, and trofosfamide has shown good efficacy and safety as an alternative in clinical trials. The efficacy of postoperative radiotherapy has been confirmed, which can reduce the local recurrence rate after surgical resection of soft tissue sarcoma. In summary, multimodal comprehensive treatment has become the main strategy for the treatment of soft tissue sarcoma. The combination of different treatment methods can generate synergistic effects and help patients obtain more clinical benefits, such as the combination of doxorubicin and immune checkpoint inhibitors, and the combination of antiangiogenic drugs and chemotherapy drugs. At the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), oncologists from all over the world reported many researches related to the treatment of soft tissue sarcoma. This article aims to review the new progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of ASCO.

Progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of the American Society of Clinical Oncology / 中华肿瘤杂志

Soft tissue sarcoma (STS) is a group of rare malignant tumors originating from mesenchymal tissue, with a high degree of malignancy and a wide range of pathological subtypes. The prognosis varies among different subtypes, and treatment increasingly relies on selecting appropriate treatment methods for different subtypes. Surgical treatment is still the main treatment method at present, and the development of immune and targeted therapy also brings new hope for the treatment of soft tissue sarcoma. Immune checkpoint inhibitors, oncolytic viruses and T cell therapy have shown well safety and efficacy in clinical trials. Targeted drugs such as trabectedin and lenvatinib have changed the treatment pattern of soft tissue sarcoma. Currently, chemotherapy based on doxorubicin and ifosfamide is still the first line treatment for patients with advanced soft tissue sarcoma who have distant metastasis. However, the adverse reactions of doxorubicin limit its application in elderly patients, and trofosfamide has shown good efficacy and safety as an alternative in clinical trials. The efficacy of postoperative radiotherapy has been confirmed, which can reduce the local recurrence rate after surgical resection of soft tissue sarcoma. In summary, multimodal comprehensive treatment has become the main strategy for the treatment of soft tissue sarcoma. The combination of different treatment methods can generate synergistic effects and help patients obtain more clinical benefits, such as the combination of doxorubicin and immune checkpoint inhibitors, and the combination of antiangiogenic drugs and chemotherapy drugs. At the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), oncologists from all over the world reported many researches related to the treatment of soft tissue sarcoma. This article aims to review the new progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of ASCO.

Efficacy and safety of Anlotinib in the treatment of advanced sarcoma / 中华肿瘤杂志

Objective: Patients with advanced sarcomas have a dismal prognosis with few effective therapies. The purpose of this study was to evaluate the efficacy and safety of anlotinib in the treatment of advanced sarcoma and to explore the relationship between adverse events (AEs) and efficacy. Methods: Data from 45 advanced sarcoma patients who received anlotinib monotherapy at Affiliated Cancer Hospital of Zhengzhou University between June 2018 and August 2021 were retrospectively analyzed. According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, the objective remission rate (ORR) and disease control rate (DCR) were calculated, and the progression free survival (PFS) and treatment-related AEs were recorded and analyzed. Survival analysis was conducted using the Kaplan-Meier survival rates were compared using the Log rank test. Results: Forty patients were treated for more than 1.5 months and received efficacy evaluation. The ORR and DCR after 3 months were 7.5%(3/40) and 80.0%(32/40), respectively. The overall ORR was 2.5%(1/40), the total DCR was 27.5%(11/40), and the median progression-free survival (m-PFS) was 6.70 months; The m-PFS of alveolar soft tissue sarcoma (ASPS) was 10.27 months, which was significantly longer than that of other subtypes of sarcoma (P=0.048). In addition, the DCR of ASPS and synovial sarcoma (SS) was significantly better than that of osteosarcoma (P<0.05). The most common AEs were elevated thyroid stimulating hormone (17.8%, 8/45), anemia (15.6%, 7/45), fatigue (11.1%, 5/45). Five patients developed grade 3 AEs after treatment; The PFS of patients with hand-foot syndrome after treatment was significantly longer than that of patients without hand-foot syndrome (14.10 vs 6.00, P=0.024). Conclusions: The efficacy of anlotinib in the treatment of ASPS and SS is better than that of other subtypes. The PFS in the group with hand-foot syndrome was significantly longer than that of the group without hand-foot syndrome.

Efficacy and safety of Anlotinib in the treatment of advanced sarcoma / 中华肿瘤杂志

Objective: Patients with advanced sarcomas have a dismal prognosis with few effective therapies. The purpose of this study was to evaluate the efficacy and safety of anlotinib in the treatment of advanced sarcoma and to explore the relationship between adverse events (AEs) and efficacy. Methods: Data from 45 advanced sarcoma patients who received anlotinib monotherapy at Affiliated Cancer Hospital of Zhengzhou University between June 2018 and August 2021 were retrospectively analyzed. According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, the objective remission rate (ORR) and disease control rate (DCR) were calculated, and the progression free survival (PFS) and treatment-related AEs were recorded and analyzed. Survival analysis was conducted using the Kaplan-Meier survival rates were compared using the Log rank test. Results: Forty patients were treated for more than 1.5 months and received efficacy evaluation. The ORR and DCR after 3 months were 7.5%(3/40) and 80.0%(32/40), respectively. The overall ORR was 2.5%(1/40), the total DCR was 27.5%(11/40), and the median progression-free survival (m-PFS) was 6.70 months; The m-PFS of alveolar soft tissue sarcoma (ASPS) was 10.27 months, which was significantly longer than that of other subtypes of sarcoma (P=0.048). In addition, the DCR of ASPS and synovial sarcoma (SS) was significantly better than that of osteosarcoma (P<0.05). The most common AEs were elevated thyroid stimulating hormone (17.8%, 8/45), anemia (15.6%, 7/45), fatigue (11.1%, 5/45). Five patients developed grade 3 AEs after treatment; The PFS of patients with hand-foot syndrome after treatment was significantly longer than that of patients without hand-foot syndrome (14.10 vs 6.00, P=0.024). Conclusions: The efficacy of anlotinib in the treatment of ASPS and SS is better than that of other subtypes. The PFS in the group with hand-foot syndrome was significantly longer than that of the group without hand-foot syndrome.

Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma

Sixteen cases of malignant soft tissue sarcoma (STS; 10 canines and six felines) were treated with a novel triple therapy that combined photodynamic therapy, hyperthermia using indocyanine green with a broadband light source, and local chemotherapy after surgical tumor resection. This triple therapy was called photodynamic hyperthermal chemotherapy (PHCT). In all cases, the surgical margin was insufficient. In one feline case, PHCT was performed without surgical resection. PHCT was performed over an interval of 1 to 2 weeks and was repeated three to 21 times. No severe side effects, including severe skin burns, necrosis, or skin suture rupture, were observed in any of the animals. No disease recurrence was observed in seven out of 10 (70.0%) dogs and three out of six (50.0%) cats over the follow-up periods ranging from 238 to 1901 days. These results suggest that PHCT decreases the risk of STS recurrence. PHCT should therefore be considered an adjuvant therapy for treating companion animals with STS in veterinary medicine.

Extracellular polysaccharide production by a strain of Pleurotus djamor isolated in the south of Brazil and antitumor activity on Sarcoma 180

Polysaccharides with medicinal properties can be obtained from fruiting bodies, mycelium and culture broth of several fungus species. This work was carried out in batch culture using a stirred tank reactor with two different initial glucose concentrations (40-50 g/L) and pH values (3.0-4.0) to enhance extracellular polysaccharides production by Pleurotus djamor UNIVILLE 001 and evaluate antitumor effect of intraperitonial administration of Pleurotus djamor extract on sarcoma 180 animal model. According to factorial design, the low pH value (pH 3.0) led to a gain of 1.6 g/L on the extracellular polysaccharide concentration, while glucose concentration in the tested range had no significant effect on the concentration of polysaccharide. With 40 g/L initial glucose concentration and pH 3.0, it was observed that yield factor of extracellular polysaccharide on substrate (Y P/S = 0.072) and maximum extracellular polysaccharide productivity (Q Pmax = 11.26 mg/L.h) were about 188% and 321% respectively higher than those obtained in the experiment performed at pH 4.0. Under these conditions, the highest values of the yield factor of biomass on substrate (Y X/S = 0.24) and maximal biomass productivity (Q Xmax = 32.2 mg/L.h) were also reached. In tumor response study, mean tumor volume on the 21th day was 35.3 cm³ in untreated group and 1.6 cm³ in treated group (p = 0.05) with a tumor inhibition rate of 94%. These impressive results suggests an inhibitory effect of P.djamor extract on cancer cells.

Chemotherapy in adult soft tissue sarcoma.

Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms. Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma. This review gives an outline of chemotherapy and the newer targeted therapies for the same. We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma. The available data from the literature is mainly composed of the most recent reviews, meta-analyses, phase II, and randomized phase III trials published in various peer reviewed journals and various international conferences. The role of neoadjuvant and adjuvant chemotherapy has been found to be controversial. The recent meta-analysis for adjuvant therapy in STSs has shown an increase in the overall survival with combination of ifosfamide and adriamycin. In locally advanced and metastatic STSs, single agent adriamycin remains the basic standard of medication. The combination of ifosfamide and adriamycin may also be used for rapid symptom relief and in patients planned for curative resection for metastases. Newer combinations of docetaxel and gemcitabine appear promising in selected subgroups, especially in leiomyosarcoma and malignant fibrous histiocytoma. Some recent developments include the European Union's approval of trabectedin for advanced STSs patients who had progressed on adriamycin and ifosfamide therapy. The future of mTOR inhibitors, insulin like growth factor receptor inhibitors and anti-angiogenic drugs appear quite promising. Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials. At the end of each section we have also presented recommendations from *European Society of Medical Oncology and **National Comprehensive Cancer Network guidelines v.1.2009 for better correlation with the present literature.

Antitumor effects of ethanolic extracts from Sophora moorcroftiana seeds in mice

Sophora moorcroftiana [Wallich] is an endemic shrub species in Tibet, China, and is a plant with a great value in folk medicine. The previous studies had shown that the ethanolic [95%] extracts were much more effective than other extracts from Sophora moorcroftiana seeds on antiproliferative effects, inducing apoptosis in the human stomach cancer SGC-7901 cell line in vitro. To investigate the antitumor activity of the ethanolic extracts from Sophora moorcroftiana seeds, various doses of ethanolic extracts [200 mg/kg/d, 400 mg/kg/d, 800 mg/Kg/d] were administered via gavage to tumorbearing mice with S180 sarcoma cell for ten days. The weights of tumor tissue stripped from the left flank, TNF-alpha and IL-2 in blood-serum were tested and analyzed for photochemical composition, using standard procedures. The weight of tumor tissue was significantly decreased upon the treatment with ethanol extracts, but the decrease was more prominent in the group receiving ethanol extracts treatment at 800 mg/kg/d [1.35 +/- 0.21mg] and the inhibition rate on the growth of tumor tissue was higher [28.1%]. The structural changes of post-treatment in the tumor tissue by the ethanolic extracts at a dose of 800 mg/kg/d showed larger areas of necrosis and more significantly invaded lymphocytes. IL-2 and TNF-alpha in serum from the treated mice significantly increased in ethanolic extract-treated groups, compared with the untreated control animals. This suggested that the ethanolic extracts from Sophora moorcroftiana seeds had a weak antitumor role and in high concentration to tumor-bearing mice in vivo, the 95% ethanolic extracts was rather effective

In vitro anti-proliferation/cytotoxic activity of epingaione and its derivatives on the human SH-SY5Y neuroblastoma and TE-671 sarcoma cells / Actividad citotóxica antiproliferativa in vitro de la epingaiona y sus derivados, sobre el neuroblastoma humano sh-sy5y y las células del sarcoma te-671

Epingaione (4-Methyl-1-(5-methyl-2, 3,4,5-tetrahydro-[2,3']bifuranyl-5-yl)-pentan-2-one) was isolated as one of the major lipophilic secondary metabolites from the leaves and stems of Bontia daphnoides L. The compound gave 79.24and 50.83anti-proliferation/cytotoxic activity on the human SH-SY5Y neuroblastoma and TE-671 sarcoma cells in vitro at 50 pg/mL, respectively. Epingaione was transformed into eleven derivatives under laboratory conditions using ethanol, some gave greater anti-proliferation/cytotoxic activity on the cancer cell lines tested. One of the derivatives (compound 2) with enhanced cytotoxic activity was elucidated as 5'-Ethoxy-5-methyl-5-(4-methyl-2-oxo-pentyl)-2,3,4,5-tetrahydro-5'H-[2,3']bifuranyl-2'-one. Both epingaione and compound 2 caused an accumulation of arrested or dead SH-SY5Y neuroblastoma in the m-phase of the cell cycle as revealed by the m-phase specific marker KE 67.

La epingaiona (4-Metil-1-(5-metil-2,3,4,5-tetrahidro-[2,3']bifuranil-5-il)-pentan-2-uno) fue aislada como uno de los principales metabolitos lipofilicos secundarios de las hojas y tallos de Bontia daphnoides L. El compuesto produjo 79.24 % y 50.83 % de actividad citotóxica/anti-proliferación sobre el neuroblastoma humano SH-SY5Y y las células del sarcoma TE-671 in vitro a 50 µg/mL, respectivamente. La epingaiona fue transformada en once derivados en condiciones de laboratorio, utilizando etanol. Algunos produjeron mayor actividad citotóxica y antiproliferativa sobre las líneas celulares cancerosas sometidas a ensayo. Uno de los derivados (compuesto 2) de elevada actividad citotóxica fue identificado como 5'-Etoxi-5-metil-5-(4-metil-2-oxo-pentil)-2,3,4,5-tetrahidro-5'H- [2,3']bifuranil-2'-uno. Tanto la epingaiona como el compuesto 22 causaron una acumulación de neuroblastomas SH-SY5Y muertos o detenidos en la fase m del ciclo celular, según lo revela el marcador KE 67 específico de la fase m.

Primitive cardiac sarcomas: about 2 cases

The cardiac sarcomas, although very rare, represent the quasi-totality of the primitive sly tumors of the heart. It is about a retrospective study of two cases of cardiac sarcomas operated in Sahloul university hospital of Sousse. Cases it is about a woman and a man: The respective ages were 22 and 45 years. The clinical pattern of the patients was polymorphic and the diagnosis put by cardiac echography. Both patients had a surgical resection and a chemotherapy. Both patients died in 13 and 18 months after the diagnosis. Because of the extreme rarity of the cardiac sarcomas, there is no precise therapeutic strategy. The only consensus concerns the surgery as soon as the diagnosis of cardiac tumor is put. The prognosis of these tumors is extremely redoubtable with a survival which does not exceed 2 years after the beginning of the symptomatology

Atividade antitumoral de indigofera suffruticosa / Antitumoractivity of indigofera suffruticosa

Objetivo: Avaliar a atividade antitumoral de extratos aquosos por infusão e maceração de folhas de Indigofera suffruticosa (Fabaceae) em camundongos albinos suíços. Materiais e Métodos: Em trinta camundongos albinos suíços foram injetados via i.p. 0,3 ml de células do Sarcoma 180 (aproximadamente 3x106 células). Após 48 horas do implante, a quimioterapia foi iniciada com o uso do extrato aquoso de folhas de I. suffruticosa por infusão e maceração em concentrações diárias de 50mg/kg i.p. por 7 dias consecutivos. Para o grupo controle, 0,2 ml/Kg i.p. de solução salina foi administrada. No oitavo dia, os camundongos foram sacrificados para estudos tumorais. Os dados foram analisados utilizando-se Análise de Variância (ANOVA) ou o teste de Kruskal-Wallis. P<0,001 foi usado para rejeição da hipótese de nulidade. Resultados: A atividade antitumoral dos extratos aquosos por infusão (64,5%) e maceração (62,6%) sob Sarcoma 180 em camundongos na dose de 50 mg/kg i.p., baseada na baixa ordem de toxicidade, foi comparada com o grupo controle que mostrou desenvolvimento tumoral de 100% Conclusão: O extrato aquoso de folhas de I. suffruticosa apresenta propriedade antitumoral.

Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats

OBJETIVO: Avaliar o potencial benéfico da histamina combinada ao melfalano, na perfusão de membro isolado (PMI), como alternativa à combinacão TNF-alfa mais melfalano, no tratamento de sarcomas de partes moles irressecaveis em extremidades, em ratos de linhagem Brown Norway (BN). MÉTODOS: 20 ratos BN foram submetidos a implantacão de fragmentos de fibrosarcoma singênico BN-175 na pata traseira direita. Em cerca de 7-10 dias o tumor atingiu um diâmetro médio de 12-15 mm e foram aleatóriamente divididos em quatro grupos (controle, melfalano,histamina em doses progessivas combinada ao melfalano e histamina) sendo submetidos a PMI experimental por 30 minutos. Os tumores foram então medidos diariamente com o uso de paquímetro e o volume tumoral calculado. RESULTADOS: As curvas de resposta mostram um efeito significativo da combinacão de Histamina na concentracão de 200 mg/mL ao melfalano, com 66% de resposta global incluindo 33% de respostas completas (p < 0.01). Não houve efeitos colaterais sistêmicos e localmente apenas edema leve e transitório nos animais tratados com histamine. CONCLUSAO: A histamina em combinacão com o melfalano apresenta um efeito promissor na PMI garantindo maiores investigacões do seu mecanismo de acão e do seu potencial uso na perfusão de órgãos.

Stromal sarcoma of breast: a case report.

A 34 years unmarried female was admitted with an ulcerated foul smelling growth in her right breast. On examination the fungating mass measured 17.5 cm x 15 cm in central and lower part of right breast involving the nipple and areola. The ulcer was covered with slough and rest part of the breast appeared bosselated. Her Hb was 4 g/dl and incision biopsy from the margin of the tumour showed histology of sarcoma. The patient was infused 6 units of blood and right sided total mastectomy was done. Histopathological examination confirmed it was a case of stromal sarcoma of breast. Chemotherapy was started with vincristine, adriamycin and cylophosphamide. The patient was doing well in next follow-up.

Sarcomas de partes moles primários de tronco e extremidades em lactentes / Primary trunk and extremities soft sarcomas in infants

Durante o período de janeiro de 1970 a dezembro de 1991, 30 lactentes portadores de sarcoma de partes moles primário do tronco e extremidades foram admitidos no Departamento de Pediatria do Hospital do Câncer. Treze neoplasias eram originárias da parede torácica e abdominal; 13, de membros inferiores; e quatro, de membros superiores. Dez pacientes apresentavam doença localizada e 20, doença avançada. Em relaçäo ao tipo histológico, 18 tumores foram classificados como sarcomas de partes moles näo rabdomiossarcoma. Quinze crianças estäo vivas sem evidência de doença; uma, viva com segundo tumor (LLA); três foram perdidos de seguimento e 11 foram a óbito (10 por progressäo de doença e um por toxicidade). A intervençäo cirúrgica, a quimioterapia e a radioterapia utilizadas isoladamente ou combinadas na dependência do tipo histológico e extensäo da doença nos pacientes portadores de sarcomas de partes moles foram responsáveis pelo aumento da taxa de cura nesses casos. As características intrínsecas do lactente fazem com que cada vez mais esses recursos terapêuticos venham a ser aprimorados a fim de que os efeitos colaterais decorrentes do tratamento sejam evitados ou minimizados. Ao analisarmos lactentes portadores de sarcomas de partes moles, pudemos avaliar os efeitos deletérios decorrentes da terapêutica preconizada nos anos 70 e 80, atentando para o fato de que cada vez mais, cura e qualidade de vida devem caminhar paralelamente. Os avanços em biologia molecular poderÝo, num futuro próximo, selecionar pacientes de maior ou menor risco, preconizando tratamentos mais e menos agressivos na dependência do prognóstico. O fator prognóstico mais importante foi a extensäo da doença ao diagnóstico.

Diagnóstico y tratamiento de los sarcomas de partes blandas / Soft tissue sarcomas, diagnosis and treatment

En este artículo se presentan algunos conocimientos básicos y avanzados sobre el estudio de los carcomas, así como de su biología y manejo multidisciplinario. También se presenta parte de las experiencias que hemos adquirido en el Instituto Nacional de Cancerología

Sarcomas de cabeza y cuello / Head and neck sarcomas

Diversos tipos de sarcomas existen en el área de cabeza y cuello, aunque por lo general son neoplasias muy raras. Se localizan en esta región el 15 por ciento de todos los sarcomas, pero representan apenas el 1 por ciento de los tumores de cabeza y cuello. Su historia natural es similar a los sarcomas del resto del cuerpo; sin embargo, dada su localización, presentan mayor dificultad quirúrgica de control local, por lo que los pacientes tienen una expectativa de vida más pobre. A diferencia de sarcomas en otra localización, éstos metastatizan preferentemente a pulmones. Se dividen en sarcomas de alto, intermedio y bajo grado, y en no clasificables. El principal factor pronóstico es el grado histológico; otros son el tamaño de la lesión, tipo de excisión (si fue o no completa) y parámetros morfológicos: (número de mitosis, pleomorfismo nuclear y necrosis). En la serie del Instituto Nacional de Cancerología de México se identificaron 27 casos (registrados entre 1082 a 1993), 23 de éstos correspondieron a sarcomas de alto grado y los cuatro restantes fueron de grado intermedio. En nuestra serie, el grado histológico también fue el principal factor pronóstico. Las estirpes de schwannoma maligno y rabdomiosarcoma fueron las variedades más frecuentes, a cada una de ellas correspondieron ocho casos (59 por ciento); también se documentarn cinco de angiosarcoma. El antro maxilar y el cuello fueron los sitios de presentación registrados con mayor frecuencia. La cirugía fue la alternativa de tratamiento en los sarcomas menores a 5 cm; mientras que la modalidad combinada se cirugía y radioterapia lo fue para lesiones mayores de 5 cm muy avanzadas. A los enfermos con tumores resecados incompletamante se les administó quimioterapia paliativa. El papel de la cirugía en sarcomas de cabeza y cuello es especialmente dificil debido a limitaciones anatómicas que dificultan dar márgenes quirúrgicos adecuado, a lo cual se suma el inherente compromiso estético y funcional. A esto habría que agregar que nuestros casos se presentaron con tumores de grandes dimensiones y ya en estadios avanzados. En conclusión, la experiencia documentada en la literatura y la obtenida en nuestro instituto apoyan el concepto de terapia combinada: cirugía y radioterapia en el tratamiento de sarcomas de alto grado resecados incompletamente; para pacientes con lesiones pequeñas y de grado intermedio...

Momento atual do tratamento dos sarcomas osseos de alta malignidade / Present status of the treatment of high grade bone sarcomas

Os autores apresentam uma revisao das alteracoes ocorridas no tratamento dos sarcomas osseos de alta malignidade nos ultimos 20 anos. Sao discutidos a abordagem multidisciplinar para o controle local e sistemico destes tumores principalmente a quimioterapia neoadjuvante que levou a um aumento na sobrevida global nao apenas para o osteossarcoma como tambem para o sarcoma de Ewing. Apresentam as possibilidades para a reconstituicao do membro apos resseccao ampla que incluem endoprotese nao convencional e enxerto autologo e de banco de osso